jdq443,tislelizumab
novartis,beigene
['sclc', 'lcsm,(-blcsm)', 'nsclc', 'kontrast01', 'novartis']
today, the updated safety and efficacy data from the kontrast01 study will be presented #nsclc #asco23 #lcsm
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu